## Verdict

verdict: PASS

```json
{"phase":"7.5","verdict":"PASS","iterations":2,"compound_risk_tier":"experimental","compound_entry_path":"vault/compounds/n-acetyl-selank-amidate.md","required_fields":{"adverse_effects_literature":"populated","contraindications":"populated","monitoring":"populated","stopping_criteria":"populated"},"third_party_monitoring_marker_present":true,"third_party_markers":["hs-CRP (immunogenicity/inflammation)","cortisol (HPA/stress)","heart rate variability (HRV)"],"halt_reasons":[]}
```

## Prose Detail (iteration 2 — PASS)

### Field-by-field verification

**adverse_effects_literature — populated**

Both files carry the full adverse-effects content: no direct analog safety data (only Selank-parent extrapolation, explicitly stated); immunogenicity/immune-sensitization from repeated SC injection of a terminally modified non-endogenous peptide; population-direction-reversal risk (psychostimulant effect therapeutic in anxious patients, potentially adverse in healthy users); binding-epitope disruption uncertainty from N-terminal acetylation; grey-market identity/purity uncertainty; acute transient hypotensive animal signal; no long-term safety data. Research-report section 5.1–5.7 and section-D D.1/D.5 confirm all four analog-specific risks are documented.

**contraindications — populated**

Both files enumerate: pregnancy/lactation; known hypersensitivity to Selank/Tuftsin/formulation components; concurrent benzodiazepine or GABAergic CNS depressant use without medical supervision; active psychiatric conditions requiring monitored pharmacotherapy; grey-market purity as an absolute injection-route constraint. Research-report section 5.7 and section-D D.5 confirm.

**monitoring — populated (FIX confirmed in BOTH files)**

All three required objective markers are present with `[[biomarkers/...]]` wiki links in both the research-report (section 5.7) and section-D (D.5):

1. **`[[biomarkers/hs-crp]]` (hs-CRP) — immunogenicity/immune-sensitization surveillance.** Research-report section 5.7 reads: *"hs-CRP is the appropriate objective inflammatory marker to track this risk: a rising hs-CRP trend on the injection schedule — absent an intercurrent infection or other identifiable cause — is the earliest laboratory signal of an immune-sensitization or subclinical inflammatory response to the peptide."* Explicitly tied to the immunogenicity risk from repeated SC injection. Section-D D.5 carries identical framing with the `[[biomarkers/hs-crp]]` link present.

2. **`[[biomarkers/cortisol]]` — HPA/stress-axis mechanism-adjacent surveillance.** Both files name morning serum or salivary cortisol as an objective correlate of stress-axis state relevant to the anxiolytic mechanism claim, explicitly labeled a surveillance adjunct rather than a validated efficacy endpoint.

3. **`[[biomarkers/hrv]]` (Heart Rate Variability) — autonomic/anxiety surveillance.** Both files name resting-state HRV via consumer wearable as a non-invasive objective time-series window on autonomic/anxiety state changes, correlated with GABAergic tone. Labeled an autonomic surveillance adjunct, not a validated efficacy biomarker.

The "no validated efficacy biomarker; monitoring largely symptom-based" honesty clause is intact in both files (section-D D.5: *"There is no validated efficacy or safety biomarker for Selank or this analog. No peer-reviewed protocol specifies laboratory monitoring for Selank use."*). All existing items from the prior placeholder state (symptom diary, blood pressure, CBC/CMP, injection-site assessment, mental health monitoring) remain present.

**stopping_criteria — populated**

Both files enumerate: worsening anxiety or emergence of panic symptoms; injection-site infection signs (fever, redness, purulence); systemic signs following injection (urticaria, flushing, dyspnea; anaphylaxis flag); significant sedation or cognitive slowing inconsistent with Selank profile (identity/contamination concern); any neurological symptoms not present at baseline; WADA-confirmed prohibition + anti-doping subject status. Section-D D.5 ("Stopping criteria — symptom-based, none biomarker-validated") and research-report section 5.7 both confirm.

### Third-party marker presence summary

| Marker | Wiki link | Rationale | In research-report | In section-D |
|--------|-----------|-----------|-------------------|--------------|
| hs-CRP | `[[biomarkers/hs-crp]]` | Immunogenicity/SC injection immune-sensitization | YES (section 5.7) | YES (D.5) |
| Cortisol | `[[biomarkers/cortisol]]` | HPA/stress-axis surveillance | YES (section 5.7) | YES (D.5) |
| HRV | `[[biomarkers/hrv]]` | Autonomic/anxiety surveillance | YES (section 5.7) | YES (D.5) |

### Gate outcome

Prior HALT condition (iteration 1): monitoring sections contained only symptom-diary/BP/CBC-CMP/injection-site items with no named objective markers; `third_party_monitoring_marker_present = false`.

Current state (iteration 2): all three named objective markers confirmed present with wiki links in both source files; all 4 required fields populated; `third_party_monitoring_marker_present = true`; `halt_reasons = []`.

Verdict: **PASS**.
